Edgewise Therapeutics boosted R&D spending in final quarter of 2024
Edgewise Therapeutics Inc., a Boulder-based muscle disease biopharmaceutical company, increased its research and development spending in the fourth quarter of fiscal 2024 as trials for its treatment of Duchenne and Becker muscular dystrophy ramped up.
THIS ARTICLE IS FOR SUBSCRIBERS ONLY
Continue reading for less than $3 per week!
Get a month of award-winning local business news, trends and insights
Access award-winning content today!
Related Posts
-
Foresight Diagnostics Inc., a Boulder-based cancer diagnostics company that specialized in the development of ultra-sensitive…
-
Edgewise Therapeutics Inc. (Nasdaq: EWTX) has promoted Behrad Derakhshan, formerly the Boulder-based muscle disease biopharmaceutical…
-
Edgewise Therapeutics has clarified its relationship with a clinical researcher who recently received a warning…
-
VitriVax Inc., a Boulder company that is developing vaccine technology, said this week that it…
